Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.
Gastric cancers with a specific protein marker (Claudin18.2) may respond to targeted drugs independently developed from other known tumor signatures, expanding treatment options.
This comprehensive review from Peking University Cancer Hospital systematically examines the biology of CLDN18.2-positive gastric cancer, its tumor microenvironment characteristics, and emerging therapeutic strategies (antibodies, ADCs, CAR-T, bispecifics). CLDN18.2 expression appears independent of HER2 and PD-L1, suggesting it represents a distinct biomarker-defined GC subpopulation with actionable therapeutic implications.
What the study was
- Study design
- Systematic narrative review
- Population
- Gastric cancer patients with CLDN18.2 expression
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Hematology & Oncology
Why it surfaced
CLDN18.2 is a clinically validated target (zolbetuximab approved 2024); review consolidates emerging data on next-generation agents and TME biology for downstream pipeline context-building.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.